Two separate court rulings on the legality of the abortion medication, mifepristone, have caused uncertainty surrounding access to the drug in the US, just a year after Roe v. Wade was overturned. U.S. District Judge Matthew Kacsmaryk overruled the FDA's scientific approval of mifepristone, essentially placing a hold on its availability, while another court in Washington, D.C., led by Judge Thomas O.